File(s) under permanent embargo
Chasing the personalized medicine dream through biomarker validation in colorectal cancer.
journal contribution
posted on 2017-01-01, 00:00 authored by Harshali Anant Patil, S G Saxena, Colin BarrowColin Barrow, Jagat Kanwar, Arnab KapatArnab Kapat, Rupinder KanwarColorectal cancer (CRC) is a major health burden worldwide. The optimal approach to the diagnosis, management, and treatment of CRC involves multidisciplinary and integrated management practices. The field is rapidly changing because of recent advancements in delineating the molecular basis of tumorigenesis, introduction of targeted therapy, varied patient response to mainstay chemotherapeutics, biological drugs, and the effective combination regimes being used for treatment. Recent meta-analysis studies, which tend to establish few clinically useful predictor biomarkers, identify inconsistent results and limitations of the trials. Therefore, molecular pathological epidemiology discipline initiatives are promising. Here, we provide an overview of the potential of biomarker validation for personalized medicine by focusing largely on metastatic (m)CRC. We also highlight new candidate predictive and prognostic biomarkers.
History
Journal
Drug discovery todayVolume
22Issue
1Pagination
111 - 119Publisher
ElsevierLocation
Amsterdam, The NetherlandsPublisher DOI
ISSN
1878-5832eISSN
1878-5832Language
engPublication classification
C Journal article; C1 Refereed article in a scholarly journalCopyright notice
2016, ElsevierUsage metrics
Categories
No categories selectedKeywords
Science & TechnologyLife Sciences & BiomedicinePharmacology & PharmacyMETHYLENETETRAHYDROFOLATE REDUCTASE C677TMOLECULAR PATHOLOGICAL EPIDEMIOLOGYISLAND METHYLATOR PHENOTYPEMONOCLONAL-ANTIBODY THERAPYDIHYDROPYRIMIDINE DEHYDROGENASEMICROSATELLITE INSTABILITYTHYMIDINE PHOSPHORYLASEA1298C POLYMORPHISMSTHYMIDYLATE SYNTHASEPIK3CA MUTATION
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC